论文部分内容阅读
目的:观察阿托伐他汀联合阿司匹林对不稳定心绞痛(unstable angina,UA)患者血清可溶性CD40配体(soluble CD40ligand,sCD40L)、基质金属蛋白酶(matrix metalloproteinase,MMP)-2浓度变化及心绞痛疗效影响。方法:将UA患者随机分为观察组(n=40)和对照组(n=40)。对照组在常规药物治疗基础上,加用阿司匹林100mg/d;观察组在对照组治疗的基础上,加用阿托伐他汀10mg,每晚1次。2组均治疗4周,治疗前后采用ELISA法检测血清中sCD40L和MMP-2浓度,观察心绞痛疗效。结果:与对照组比较,观察组在改善心绞痛症状及降低血清中sCD40L和MMP-2浓度方面均明显优于对照组(P<0.05或P<0.01)。结论:阿托伐他汀联合阿司匹林可通过降低sCD40L和MMP-2浓度,抑制炎症反应,稳定动脉斑块,从而改善心绞痛临床症状。
Objective: To investigate the effects of atorvastatin combined with aspirin on serum soluble CD40 ligand (sCD40L), matrix metalloproteinase (MMP) -2 and angina pectoris in patients with unstable angina (UA). Methods: UA patients were randomly divided into observation group (n = 40) and control group (n = 40). The control group was given aspirin 100mg / d on the basis of conventional drug treatment. The observation group was treated with atorvastatin 10mg once a night on the basis of the control group. The two groups were treated for 4 weeks. Serum levels of sCD40L and MMP-2 were measured by ELISA before and after treatment, and angina pectoris was observed. Results: Compared with the control group, the observation group was significantly better than the control group (P <0.05 or P <0.01) in improving the symptoms of angina pectoris and lowering the serum sCD40L and MMP-2 levels. Conclusion: Atorvastatin combined with aspirin can improve the clinical symptoms of angina pectoris by reducing the concentration of sCD40L and MMP-2, inhibiting the inflammatory reaction and stabilizing the arterial plaque.